| Width | 250px |
|---|---|
| Class | Serotonin releasing agent; Entactogen |
| Atc prefix | None |
| Legal status | Uncontrolled |
| Index2 label | hydrochloride |
| Cas number | 101625-35-8 |
| Cas number 2 | 3446-21-8 |
| Unii | 28IR5LC41Q |
| Unii 2 | BOX4U52EET |
| Pubchem | 36483 |
| Chemspiderid | 33531 |
| Synonyms | 6,7-MDAT; 6,7-Methylenedioxy-2-aminotetralin |
| Iupac name | 5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxol-6-amine |
| C | 11 |
| H | 13 |
| N | 1 |
| O | 2 |
| Smiles | C3Cc1cc2OCOc2cc1CC3N |
MDAT, also known as 6,7-methylenedioxy-2-aminotetralin, is a drug of the 2-aminotetralin family developed in the 1990s by a team at Purdue University led by David E. Nichols.[1] It appears to act as a serotonin releasing agent based on rodent drug discrimination assays comparing it to MDMA, in which it fully substitutes for, and additionally lacks any kind of serotonergic neurotoxicity.[1] Hence, MDAT is considered likely to be a non-neurotoxic, putative entactogen in humans.
See also
References
- ^ Nichols DE, Brewster WK, Johnson MP, Oberlender R, Riggs RM (February 1990). "Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA)". Journal of Medicinal Chemistry. 33 (2): 703–10. doi:10.1021/jm00164a037. PMID 1967651